Literature DB >> 10802712

TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice.

D Zhang1, V Gaussin, G E Taffet, N S Belaguli, M Yamada, R J Schwartz, L H Michael, P A Overbeek, M D Schneider.   

Abstract

The transforming-growth-factor-beta-activated kinase TAK1 is a member of the mitogen-activated protein kinase kinase kinase family, which couples extracellular stimuli to gene transcription. The in vivo function of TAK1 is not understood. Here, we investigated the potential involvement of TAK1 in cardiac hypertrophy. In adult mouse myocardium, TAK1 kinase activity was upregulated 7 days after aortic banding, a mechanical load that induces hypertrophy and expression of transforming growth factor beta. An activating mutation of TAK1 expressed in myocardium of transgenic mice was sufficient to produce p38 mitogen-activated protein kinase phosphorylation in vivo, cardiac hypertrophy, interstitial fibrosis, severe myocardial dysfunction, 'fetal' gene induction, apoptosis and early lethality. Thus, TAK1 activity is induced as a delayed response to mechanical stress, and can suffice to elicit myocardial hypertrophy and fulminant heart failure.

Entities:  

Keywords:  NASA Discipline Cardiopulmonary; NASA Program Biomedical Research and Countermeasures; Non-NASA Center

Mesh:

Substances:

Year:  2000        PMID: 10802712     DOI: 10.1038/75037

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  105 in total

1.  Serial killer: angiotensin drives cardiac hypertrophy via TGF-beta1.

Authors:  Michael D Schneider
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

Review 2.  Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia.

Authors:  Razi Khan; Richard Sheppard
Journal:  Immunology       Date:  2006-05       Impact factor: 7.397

3.  Tumor suppressor A20 protects against cardiac hypertrophy and fibrosis by blocking transforming growth factor-beta-activated kinase 1-dependent signaling.

Authors:  He Huang; Qi-Zhu Tang; Ai-Bing Wang; Manyin Chen; Ling Yan; Chen Liu; Hong Jiang; Qinglin Yang; Zhou-Yan Bian; Xue Bai; Li-Hua Zhu; Lang Wang; Hongliang Li
Journal:  Hypertension       Date:  2010-06-28       Impact factor: 10.190

Review 4.  Death begets failure in the heart.

Authors:  Roger S-Y Foo; Kartik Mani; Richard N Kitsis
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

Review 5.  Re-employment of developmental transcription factors in adult heart disease.

Authors:  Toru Oka; Jian Xu; Jeffery D Molkentin
Journal:  Semin Cell Dev Biol       Date:  2006-11-24       Impact factor: 7.727

6.  Ivabradine improved left ventricular function and pressure overload-induced cardiomyocyte apoptosis in a transverse aortic constriction mouse model.

Authors:  Yihui Yu; Zuoying Hu; Bing Li; Zhimei Wang; Shaoliang Chen
Journal:  Mol Cell Biochem       Date:  2018-05-22       Impact factor: 3.396

7.  Cardiomyocyte cell cycle activation ameliorates fibrosis in the atrium.

Authors:  Hidehiro Nakajima; Hisako O Nakajima; Klaus Dembowsky; Kishore B S Pasumarthi; Loren J Field
Journal:  Circ Res       Date:  2005-11-23       Impact factor: 17.367

Review 8.  Transient receptor potential (TRP) channels and cardiac fibrosis.

Authors:  Zhichao Yue; Yanhui Zhang; Jia Xie; Jianmin Jiang; Lixia Yue
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

9.  Network-based predictions of in vivo cardiac hypertrophy.

Authors:  Deborah U Frank; Matthew D Sutcliffe; Jeffrey J Saucerman
Journal:  J Mol Cell Cardiol       Date:  2018-07-17       Impact factor: 5.000

10.  Extracellular superoxide dismutase protects the heart against oxidative stress and hypertrophy after myocardial infarction.

Authors:  Elza D van Deel; Zhongbing Lu; Xin Xu; Guangshuo Zhu; Xinli Hu; Tim D Oury; Robert J Bache; Dirk J Duncker; Yingjie Chen
Journal:  Free Radic Biol Med       Date:  2007-12-15       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.